Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

NCT04731467 is registered in ClinicalTrials.gov with Famewave Ltd. as lead sponsor.

NCT NCT04731467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04731467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Lead sponsor
Famewave Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
March 19, 2021
Completion date
September 30, 2024
Enrollment
79 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, melanoma, non small cell lung cancer, ovarian cancer, pancreatic cancer, papillary thyroid cancer, solid tumor